All In Biotech

Drug Trial Radar · NCT00316524

A Randomized, Double-blind, Placebo-controlled Study on Immunogenicity and Safety of MVA-BN (IMVAMUNE™) Smallpox Vaccine in Healthy Subjects

A Partially Randomized, Partially Double-blind, Placebo-controlled Phase II Non-inferiority Study to Evaluate Immunogenicity and Safety of One and Two Doses of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in 18-55 Year Old Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Mar 6, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 745 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

745

Actual

Start

Apr 2006

Primary completion

Feb 2007

Study completion Aug 2007

Sponsor

Lead sponsor
Bavarian NordicIndustry
Sponsor type
Industry
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
First posted
Apr 21, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the immune response after a single vaccination of pre-immune subjects compared to two vaccinations in naive subjects. In addition the study further investigates the cardiac safety profile of MVA-BN® in a healthy population compared to placebo.

Conditions

  • Smallpox

Interventions

  • MVA-BN® (IMVAMUNE)Biological

    1x 10E8\_TCID50

  • PlaceboBiological

    Tris-Buffer

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Seroconversion by ELISATime frame: 2 weeks following the last vaccination (Week 6 for Groups 1-3, Week 2 for Group 4)
  2. Number of Participants With ECG ChangesTime frame: within 2 weeks after each vaccination
  3. Number of Cardiac Adverse Events (Adverse Events of Special Interest [AESI])Time frame: within 32 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Harrison Clinical Research GmbH

    Munich, Bavaria, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.